The Indian Council of Medical Research (ICMR) has approved 21 institutions for conducting plasma therapy to limit complications associated with COVID-19.
The therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those antibodies into an active coronavirus patient.
Currently, the ICMR does not recommend this as a treatment option outside of clinical trials.